Molecular Typing of Legionella pneumophila and Legionella spp. Strains, isolated in the Russian Federation | CMAC

Molecular Typing of Legionella pneumophila and Legionella spp. Strains, isolated in the Russian Federation

Clinical Microbiology and Antimicrobial Chemotherapy. 2008; 10(2):154-162

​ Voronina O.L., Kunda M.S., Lunin V.G., Karpova T.I., Tartakovskiy I.S.
SBT and EQA protocols of EWGLI legionellosis Legionella pneumophila Legionella spp strains allelic profile
Section
Diseases and Pathogens
Type
Journal article
Publication
Clinical Microbiology and Antimicrobial Chemotherapy. 2008; 10(2):154-162

Abstract

On the base of international standarts of molecular-genetic typing (SBT protocol and EQA scheme using DNA sequencing of the mip-gene of the European Working Group for Legionella Infections — EWGLI) were descibed the strains of Legionella pneumophila and Legionella species, isolated in the Russian Federation during the last years at the monitoring and at the epidemic outbreak, and strains, presented in Gamaleya Institute Collection of Legionellosis (GICL). It was determined that 31 new strains from 3 Russian Federation’s regions belonged to 19 allelic profiles. It was revealed, that profiles 1, 4, 3, 1, 1, 1, 6 и 6, 10, 19, 28, 19, 4, 3 were most prevalent among the native strains. 9 new allelic profiles were identified, which were not earlier submitted in EWGLI base. On the base of EQA scheme using sequencing of the mip-gene the species identification of three new Legionella’s strains were made: 2 — L. gratiana and 1 — L. gormanii. The identified strains were not tested in the RF’s territory earlier.

  • 1. Kollef M.H. Prevention of hospital-associated pneumonia and ventilator-associated pneumonia. Crit Care Med 2004; 32:1396-405.
  • 2. Richards M.J., Edwards J.R., Culver D.H., Gaynes R.P. Nosocomial infections in medical intensive care units in the United States. National Nosocomial Infections Surveillance System. Crit Care Med 1999; 27:887-92.
  • 3. Hospital-acquired pneumonia in adults: diagnosis, assessment of severity, initial antimicrobial therapy, and preventive strategies: a consensus statement, American Thoracic Society, November 1995. Am J Respir Crit Care Med 1996; 153:1711-25.
  • 4. Rello J., Ollendorf D.A., Oster G., et al. Epidemiology and outcomes of ventilator-associated pneumonia in a large US database. Chest 2002; 122:2115-21.
  • 5. National Nosocomial Infections Surveillance (NNIS) system report, data summary from January 1992-April 2000, issued June 2000. Am J Infect Control 2000; 28:429-48.
  • 6. Heyland D.K., Cook D.J., Griffith L., Keenan S.P., BrunBuisson C. The attributable morbidity and mortality of ventilator-associated pneumonia in the critically ill patient. The Canadian Critical Trials Group. Am J Respir Crit Care Med 1999; 159:1249-56.
  • 7. Warren D.K., Shukla S.J., Olsen M.A., et al. Outcome and attributable cost of ventilator-associated pneumonia among intensive care unit patients in a suburban medical center. Crit Care Med 2003; 31:1312-7.
  • 8. Shorr A.F., Susla G.M., Kollef M.H. Linezolid for treatment of ventilator-associated pneumonia: a cost-effective alternative to vancomycin. Crit Care Med 2004; 32:137- 43.
  • 9. Hospital-acquired Pneumonia Guideline Committee of the American Thoracic Society and Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005; 171:388–416.
  • 10. Rello J., Rue M., Jubert P., et al. Survival in patients with nosocomial pneumonia: impact of the severity of illness and the etiologic agent. Crit Care Med 1997; 25:1862-7.
  • 11. Hanes S.D., Demirkan K., Tolley E., et al. Risk factors for late-onset nosocomial pneumonia caused by Stenotrophomonas maltophilia in critically ill trauma patients. Clin Infect Dis 2002; 35:228-35.
  • 12. Rello J., Sole-Violan J., Sa-Borges M., et al. Pneumonia caused by oxacillin-resistant Staphylococcus aureus treated with glycopeptides. Crit Care Med 2005; 33:1983-7.
  • 13. Chastre J., Fagon J.Y. Ventilator-associated pneumonia. Am J Respir Crit Care Med 2002; 165:867-903.
  • 14. Lynch J.P. Hospital-acquired pneumonia: risk factors, microbiology, and treatment. Chest 2001; 119 (2 Suppl): 373S -384S.
  • 15. Combes A., Figliolini C., Trouillet J.L, et al. Incidence and outcome of polymicrobial ventilator-associated pneumonia. Chest 2002; 121:1618 –23.
  • 16. Ibrahim E.H., Ward S., Sherman G., Kollef M.H. A comparative analysis of patients with early-onset vs lateonset nosocomial pneumonia in the ICU setting. Chest 2000; 117:1434-42.
  • 17. Flanders S.A., Collard H.R., Saint S. Nosocomial pneumonia: state of the science. Am J Infect Control 2006; 34:84-93.
  • 18. Dore P., Robert R., Grollier G., et al. Incidence of anaerobes in ventilator-associated pneumonia with use of a protected specimen brush. Am J Respir Crit Care Med 1996; 153:1292–8.
  • 19. Marik P.E., Careau P. The role of anaerobes in patients with ventilator-associated pneumonia and aspiration pneumonia: a prospective study. Chest 1999; 115:178– 83.
  • 20. Morehead R.S., Pinto S.J. Ventilator-associated pneumonia. Arch Intern Med 2000; 160:1926-36.
  • 21. Fagon J.Y., Chastre J., Domart Y., et al. Nosocomial pneumonia in patients receiving continuous mechanical ventilation. Prospective analysis of 52 episodes with use of a protected specimen brush and quantitative culture techniques. Am Rev Respir Dis 1989; 139:877-84.
  • 22. Torres A., Aznar R., Gatell J.M., et al. Incidence, risk, and prognosis factors of nosocomial pneumonia in mechanically ventilated patients. Am Rev Respir Dis 1990; 142:523-8.
  • 23. Rello J., Sa-Borges M., Correa H., Leal S.R., Baraibar J. Variations in etiology of ventilator-associated pneumonia across four treatment sites: implications for antimicrobial prescribing practices.Am J Respir Crit Care Med. 1999; 160:608-13.
  • 24. Страчунский Л.С., Решедько Г.К., Рябкова Е.Л. и др. Рекомендации по оптимизации антимикробной терапии нозокомиальных инфекций, вызванных грамотрицательными бактериями в отделениях реанимации и интенсивной терапии. Клин микробиол антимикроб химиотер 2002; 4: 379-90.
  • 25. Reshedko G., Sukhorukova M., Ivanchik N., et al. Antimicrobial resistance of nosocomial gram-negative bacteria in Russian Intensive Care Units (ICUs). Proceedings of the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy, 2007, abst. 1539.
  • 26. Kollef M.H., Kollef K.E. Antibiotic utilization and outcomes for patients with clinically suspected ventilatorassociated pneumonia and negative quantitative BAL culture results. Chest 2005; 128:2706 –13.
  • 27. Luna C.M., Videla A., Mattera J., et al. Blood cultures have limited value in predicting severity of illness and as a diagnostic tool in ventilator-associated pneumonia. Chest 1999; 116:1075–84.
  • 28. Muscedere J., Dodek P., Keenan S., Fowler R., Cook D., Heyland D.; for the VAP Guidelines Committee and the Canadian Critical Care Trials Group. Comprehensive evidence-based clinical practice guidelines for ventilatorassociated pneumonia: Diagnosis and treatment. J Crit Care 2008; 23:138-47.
  • 29. Kollef M.H., Ward S. The influence of mini-BAL cultures on patient outcomes: implications for the antibiotic management of ventilator-associated pneumonia. Chest 1998; 113:412-20.
  • 30. Clec’h C., Timsit J.F., De Lassence A., et al. Efficacy of adequate early antibiotic therapy in ventilator-associated pneumonia: influence of disease severity. Intensive Care Med 2004; 30:1327-33.
  • 31. Iregui M., Ward S., Sherman G., Fraser V.J., Kollef M.H. Clinical importance of delays in the initiation of appropriate antibiotic treatment for ventilator-associated pneumonia. Chest 2002; 122:262-8.
  • 32. Dupont H., Mentec H., Sollet J.P., Bleichner G. Impact of appropriateness of initial antibiotic therapy on the outcome of ventilator-associated pneumonia. Intensive Care Med 2001; 27:355-62.
  • 33. Alvarez-Lerma F., ICU-acquired Pneumonia Study Group. Modification of empiric antibiotic treatment in patients with pneumonia acquired in the intensive care unit. Intensive Care Med 1996; 22:387–94.
  • 34. Luna C.M., Vujacich P., Niederman M.S., et al. Impact of BAL data on the therapy and outcome of ventilatorassociated pneumonia. Chest 1997; 111:676-85.
  • 35. Celis R., Torres A., Gatell J.M., Almela M., RodriguezRoisin R., Agusti-Vidal A. Nosocomial pneumonia: a multivariate analysis of risk and prognosis. Chest 1988; 93:318-24.
  • 36. Чучалин А.Г., Синопальников А.И., Страчунский Л.С. и др. Нозокомиальная пневмония у взрослых: практические рекомендации по диагностике, лечению, профилактике. Пособие для врачей. Москва, 2005. 54 с.
  • 37. Pea F., Viale P., Furlanut M. Antimicrobial therapy in critically ill patients. Clin Pharmacokinet 2005; 44:1009- 34.
  • 38. Pinder M., Bellomo R., Lipman J. Pharmacological principles of antibiotic prescription in the critically ill. Anaesth Intensive Care 2002; 30:134-44.
  • 39. Park D. Antimicrobial treatment of ventilator-associated pneumonia. Resp Care 2005; 507:932-52.
  • 40. Craig W.A. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998; 261:1-10.
  • 41. Bernabeu-Wittel M., Pichardo C., García-Curiel A., et al. Pharmacokinetic/pharmacodynamic assessment of the in vivo efficacy of imipenem alone or in combination with amikacin for the treatment of experimental multiresistant Acinetobacter baumannii pneumonia. Clin Microbiol Infect 2005; 11:319-25.
  • 42. Siempos I.I., Vardakas K.Z., Manta K.G., Falagas M.E. Carbapenems for the treatment of immunocompetent adult patients with nosocomial pneumonia. Eur Respir J 2007; 29:548-60.
  • 43. Alvarez-Lerma F., Santos F.M., De Castro J., et al. Efficacy of meropenem as monotherapy in the treatment of ventilator-associated pneumonia. J Chemother 2001; 13:70-81.
  • 44. Sieger B., Berman S.J., Geckler R.W., Farkas S.A. Empiric treatment of hospital-acquired lower respiratory tract infections with meropenem or ceftazidime with tobramycin: a randomized study. Meropenem Lower Respiratory Infection Group. Crit Care Med 1997; 25:1663-70.
  • 45. Aarts M.A., Hancock J.N., Heyland D., McLeod R.S., Marshall J.C. Empiric antibiotic therapy for suspected ventilator-associated pneumonia: a systematic review and meta-analysis of randomized trials. Crit Care Med 2008; 36:108-17.
  • 46. Heyland D.K., Dodek P., Muscedere J., Day A., Cook D.; for the Canadian Critical Care Trials Group. Randomized trial of combination versus monotherapy for the empiric treatment of suspected ventilator-associated pneumonia. Crit Care Med. 2007 Dec 12.
  • 47. Rello J., Vidaur L., Sandiumenge A., et al. De-escalation therapy in ventilator-associated pneumonia. Crit Care Med 2004; 32:2183-90.
  • 48. Ibrahim E.H., Ward S., Sherman G., Schaiff R., Fraser V.J., Kollef M.H. Experience with a clinical guideline for the treatment of ventilator-associated pneumonia. Crit Care Med 2001; 29:1109-15.
  • 49. Kollef M.H., Niederman M.S., Leeper K.V., et al. Escalation/de-escalation of initial empiric ventilatorassociated pneumonia therapy: interim results from the Assessment of Local Antimicrobial Resistance Measures study. Chest 2004; 126:718S.
  • 50. Yan X.X., Zhang L.J., Cai Z.G., et al. A study of the effectiveness and cost of de-escalation therapy for severe lower airway infection in a respiratory intensive care unit. Zhonghua Jie He He Hu Xi Za Zhi 2007; 30:325-9.
  • 51. Singh N., Rogers P., Atwood C.W., Wagener M.M., Yu V.L. Short-course empiric antibiotic therapy for patients with pulmonary infiltrates in the intensive care unit. A proposed solution for indiscriminate antibiotic prescription. Am J Respir Crit Care Med 2000; 162 (2 Pt 1):505- 11.
  • 52. Chastre J., Wolff M., Fagon J.Y., et al. Comparison of 8 versus 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial. JAMA 2003; 290:2588-98.
  • 53. Micek S.T., Ward S., Fraser V.J., Kollef M.H. A randomized controlled trial of an antibiotic discontinuation policy for clinically suspected ventilator-associated pneumonia. Chest 2004; 125:1791-9.
  • 54. Dennesen P.J., Van Der Ven A.J, Kessels A.G., et al. Resolution of infectious parameters after antimicrobial therapy in patients with ventilator-pneumonia. Am J Respir Cri. Care Med 2001; 163:1371-5.
  • 55. Hedrick T.L., McElearney S.T., Smith R.L., Evans H.L., Pruett T.L., Sawyer R.G. Duration of antibiotic therapy for ventilator-associated pneumonia caused by nonfermentative gram-negative bacilli. Surg Infect 2007; 8:589-97.
  • 56. Ioannidou E., Siempos I.I., Falagas M.E. Administration of antimicrobials via the respiratory tract for the treatment of patients with nosocomial pneumonia: a metaanalysis. J Antimicrob Chemother. 2007; 60:1216-26.
  • 57. Koulenti D., Rello J. Hospital-acquired pneumonia in the 21st century: a review of existing treatment options and their impact on patient care. Expert Opin Pharmacother 2006; 7:1555-69.
  • 58. Garnacho J., Sole-Violan J., Sa-Borges M., Diaz E., Rello J. Clinical impact of pneumonia caused by Acinetobacter baumannii in intubated patients: a matched cohort study. Crit Care Med 2003; 31:2478-82.
  • 59. Falagas M., Kopterides P., Siempos I. Attributable mortality of Acinetobacter baumannii infection among critically ill patients. Clin Infect Dis. 2006;43:389.
  • 60. Albrecht M., Griffith M., Murray C., et al. Impact of Acinetobacter infection on the mortality of burn patients. J Am Coll Surg 2006; 203:546–50.
  • 61. Sunenshine R., Wright M., Maragakis L. Multidrug-resistant Acinetobacter infection mortality rate and length of hospitalization. Emerg Infect Dis 2007; 13:97–103.
  • 62. Garnacho-Montero J., Ortiz-Leyba C., FernándezHinojosa E., et al. Acinetobacter baumannii ventilatorassociated pneumonia: epidemiological and clinical findings. Intensive Care Med. 2005 May;31(5):649-55.
  • 63. Suwangpool P., Leelasupasri S., Chuchottaworn C. Treatment of nosocomial pneumonia with cefoperazone/ sulbactam. J Infect Dis Antimicrob Agents 1999; 16: 65- 8.
  • 64. Paterson D.L., Ko W.C., Von Gottberg A., e.a. Antibiotic therapy for Klebsiella pneumoniae bacteremia: implications of production of extended-spectrum β-lactamases. Clin Infect Dis 2004; 39: 31-7.
  • 65. Byl B., Jacobs F., Roucloux I., de Franquen P., Cappello M., Thys J.P. Penetration of meropenem in lung, bronchial mucosa, and pleural tissues. Antimicrob Agents Chemother 1999; 43:681-2.
  • 66. Tomaselli F., Maier A., Matzi V., Smolle-Jüttner F.M., Dittrich P. Penetration of meropenem into pneumonic human lung tissue as measured by in vivo microdialysis. Antimicrob Agents Chemother 2004; 48:2228-32.
  • 67. Odenholt-Tornqvist I. Studies on the postantibiotic effect and the postantibiotic sub-MIC effect of meropenem. J Antimicrob Chemother 1993; 31:881-92.
  • 68. Hanberger H., Svensson E., Nilsson L.E., Nilsson M. Control-related effective regrowth time and post-antibiotic effect of meropenem on gram-negative bacteria studied by bioluminescence and viable counts.J Antimicrob Chemother 1995; 35:585-92.
  • 69. Hanberger H., Svensson E., Nilsson L.E., Nilsson M. Pharmacodynamic effects of meropenem on gram-negative bacteria. Eur J Clin Microbiol Infect Dis 1995; 14:383-90.
  • 70. Hikida M., Yamazaki Y., Yoshida M., Kawashima K., Nishiki K., Mitsuhashi S. Postantibiotic effect of carbapenems against Pseudomonas aeruginosa. J Antibiot 1995; 48:891-2.
  • 71. Conte J.E., Golden J.A., Kelley M.G., Zurlinden E. Intrapulmonary pharmacokinetics and pharmacodynamics of meropenem. Int J Antimicrob Agents 2005; 26:449- 56.
  • 72. Colardyn F., Faulkner K.L. Intravenous meropenem versus imipenem/cilastatin in the treatment of serious bacterial infections in hospitalized patients. J Antimicrob Chemother 1996; 38:523-37.
  • 73. Garau J., Blanquer J., Cobo L., et al. Prospective, randomized, multicentre study of meropenem versus imipenem/ cilastatin as empiric monotherapy in severe nosocomial infections. Eur J Clin Microbiol Infect Dis 1997; 16:789- 96.
  • 74. Hartenauer U., Kljucar S., Bender H.-J., Weilemann S., Nusser H., Bodmann K.F. Meropenam versus imipenem/ cilastatin for the treatment of serious bacterial infectious in ICU. Antiinfective Drugs Chemotherapy 1997; 15:65- 70.
  • 75. Santos S.S., Machado F.R., Kiffer C.R., Barone A.A. Treatment of nosocomial pneumonia: an experience with meropenem. Braz J Infect Dis 2001; 5:124-9.
  • 76. Berman S.J., Fogarty C.M., Fabian T., et al. Meropenem monotherapy for the treatment of hospital-acquired pneumonia: results of a multicenter trial. J Chemother 2004; 16:362 –71.
  • 77. Verwaest C., Belgian Multicenter Study Group. Meropenem versus imipenem/cilastatin as empirical monotherapy for serious bacterial infections in the intensive care unit. Clin Microbiol Infect 2000; 6:294-302.
  • 78. Lorente L., Lorenzo L., Martin M.M., Jimenez A., Mora M.L. Meropenem by continuous versus intermittent infusion in ventilator-associated pneumonia due to gramnegative bacilli. Ann Pharmacother 2006; 40:219-23.
Views
0 Abstract
0 PDF
0 Crossref citations
Shared